Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

BIZARRE: Looking into mirum pharmaceuticals s return on capital employed - What They Never Told You

Pulled from Benzinga Pro data, Mirum Pharmaceuticals (NASDAQ:MIRM) posted Q4 earnings of $57.55 million, an increase from Q3 of 222.16%. Sales dropped to $3.14 million, a 37.24% decrease between quarters. In Q3, Mirum Pharmaceuticals brought in $5.00 million in sales but lost $47.11 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.